^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    tobemstomig (RG6139)

    i
    Other names: RG6139, RO7247669, PD1-LAG3 BsAb
    Associations

    News

    Trials
    Company:
    Roche
    Drug class:
    PD1 inhibitor, LAG-3 inhibitor
    Related drugs:
    Associations

    News

    Trials
    4d
    A Study of Tobemstomig Plus Platinum-Based Chemotherapy vs Pembrolizumab Plus Platinum-Based Chemotherapy in Participants With Previously Untreated Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=180, Recruiting, Hoffmann-La Roche | Active, not recruiting --> Recruiting
    Enrollment open • Metastases
    |
    PD-L1 (Programmed death ligand 1)
    |
    Keytruda (pembrolizumab) • carboplatin • paclitaxel • pemetrexed • tobemstomig (RG6139)
    6d
    A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Melanoma (Morpheus-Melanoma) (clinicaltrials.gov)
    P1/2, N=110, Completed, Hoffmann-La Roche | Recruiting --> Completed | N=336 --> 110 | Trial completion date: Jul 2025 --> Mar 2024 | Trial primary completion date: Jan 2025 --> Sep 2023
    Trial completion • Enrollment change • Trial completion date • Trial primary completion date
    |
    CD4 (CD4 Molecule)
    |
    Opdivo (nivolumab) • Tecentriq (atezolizumab) • Yervoy (ipilimumab) • tiragolumab (RG6058) • tobemstomig (RG6139)
    29d
    A Study of Tobemstomig Plus Platinum-Based Chemotherapy vs Pembrolizumab Plus Platinum-Based Chemotherapy in Participants With Previously Untreated Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=180, Active, not recruiting, Hoffmann-La Roche | Recruiting --> Active, not recruiting
    Enrollment closed • Metastases
    |
    PD-L1 (Programmed death ligand 1)
    |
    Keytruda (pembrolizumab) • carboplatin • paclitaxel • pemetrexed • tobemstomig (RG6139)
    2ms
    A Study Evaluating The Efficacy and Safety of Neoadjuvant Immunotherapy Combinations in Patients With Surgically Resectable Hepatocellular Carcinoma (clinicaltrials.gov)
    P1/2, N=150, Recruiting, Hoffmann-La Roche | Trial completion date: Feb 2027 --> Sep 2028 | Trial primary completion date: May 2025 --> Sep 2025
    Trial completion date • Trial primary completion date
    |
    Avastin (bevacizumab) • Tecentriq (atezolizumab) • tiragolumab (RG6058) • tobemstomig (RG6139)
    5ms
    A Study of Multiple Doses of RO7247669 in Participants With Previously Untreated Unresectable or Metastatic Melanoma (clinicaltrials.gov)
    P1/2, N=80, Recruiting, Hoffmann-La Roche | Phase classification: P2 --> P1/2
    Phase classification • Metastases
    |
    PD-L1 (Programmed death ligand 1) • BRAF (B-raf proto-oncogene)
    |
    BRAF mutation • BRAF V600
    |
    tobemstomig (RG6139)
    9ms
    A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Melanoma (Morpheus-Melanoma) (clinicaltrials.gov)
    P1/2, N=336, Recruiting, Hoffmann-La Roche | Trial primary completion date: Oct 2024 --> Jan 2025
    Trial primary completion date
    |
    CD4 (CD4 Molecule)
    |
    Opdivo (nivolumab) • Tecentriq (atezolizumab) • Yervoy (ipilimumab) • tiragolumab (RG6058) • tobemstomig (RG6139)
    9ms
    A global, multicentre, open-label, randomised phase II trial of tobemstomig (tobe) with or without tiragolumab (tira) vs atezolizumab (atezo) in patients (pts) with untreated metastatic urothelial cancer (mUC) ineligible for platinum-based chemotherapy (chemo) (ESMO 2023)
    This study will evaluate the effect of tobe and tobe + tira on investigator-assessed confirmed ORR (primary endpoint) relative to atezo. Secondary endpoints include PFS, OS, DOR, DCR and safety.
    P2 data • Clinical • PD(L)-1 Biomarker • IO biomarker • Metastases
    |
    LAG3 (Lymphocyte Activating 3) • TIGIT (T Cell Immunoreceptor With Ig And ITIM Domains 2)
    |
    PD-L1 expression
    |
    VENTANA PD-L1 (SP263) Assay
    |
    Tecentriq (atezolizumab) • tiragolumab (RG6058) • tobemstomig (RG6139)
    10ms
    A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Melanoma (Morpheus-Melanoma) (clinicaltrials.gov)
    P1/2, N=336, Recruiting, Hoffmann-La Roche | N=191 --> 336 | Trial completion date: Mar 2024 --> Jul 2025 | Trial primary completion date: Nov 2023 --> Oct 2024
    Enrollment change • Trial completion date • Trial primary completion date
    |
    CD4 (CD4 Molecule)
    |
    Opdivo (nivolumab) • Tecentriq (atezolizumab) • Yervoy (ipilimumab) • tiragolumab (RG6058) • tobemstomig (RG6139)
    10ms
    A Study of Lomvastomig (RO7121661) and Tobemstomig (RO7247669) Compared With Nivolumab in Participants With Advanced or Metastatic Squamous Cell Carcinoma of the Esophagus (clinicaltrials.gov)
    P2, N=210, Active, not recruiting, Hoffmann-La Roche | Recruiting --> Active, not recruiting
    Enrollment closed • IO biomarker • Metastases
    |
    CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • LAG3 (Lymphocyte Activating 3) • HAVCR2 (Hepatitis A Virus Cellular Receptor 2) • CD4 (CD4 Molecule)
    |
    CD8 expression • LAG3 expression
    |
    Opdivo (nivolumab) • lomvastomig (RG7769) • tobemstomig (RG6139)
    11ms
    A Study Evaluating The Efficacy and Safety of Neoadjuvant Immunotherapy Combinations in Patients With Surgically Resectable Hepatocellular Carcinoma (clinicaltrials.gov)
    P1/2, N=150, Not yet recruiting, Hoffmann-La Roche
    New P1/2 trial
    |
    Avastin (bevacizumab) • Tecentriq (atezolizumab) • tiragolumab (RG6058) • tobemstomig (RG6139)
    11ms
    A Study of RO7247669 + Nab-Paclitaxel Compared With Pembrolizumab + Nab-Paclitaxel in Participants With Previously Untreated, PD-L1-Positive, Locally-Advanced Unresectable or Metastatic Triple-Negative Breast Cancer (clinicaltrials.gov)
    P2, N=160, Recruiting, Hoffmann-La Roche | Not yet recruiting --> Recruiting
    Enrollment open • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • ER (Estrogen receptor) • CD4 (CD4 Molecule)
    |
    PD-L1 expression • PGR expression
    |
    Keytruda (pembrolizumab) • albumin-bound paclitaxel • tobemstomig (RG6139)
    12ms
    A Study of RO7247669 + Nab-Paclitaxel Compared With Pembrolizumab + Nab-Paclitaxel in Participants With Previously Untreated, PD-L1-Positive, Locally-Advanced Unresectable or Metastatic Triple-Negative Breast Cancer (clinicaltrials.gov)
    P2, N=160, Not yet recruiting, Hoffmann-La Roche
    New P2 trial • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • ER (Estrogen receptor) • CD4 (CD4 Molecule)
    |
    PD-L1 expression • PGR expression
    |
    Keytruda (pembrolizumab) • albumin-bound paclitaxel • tobemstomig (RG6139)
    1year
    A Study of Tobemstomig Plus Platinum-Based Chemotherapy vs Pembrolizumab Plus Platinum-Based Chemotherapy in Participants With Previously Untreated Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=180, Recruiting, Hoffmann-La Roche
    New P2 trial • IO biomarker • Metastases
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Keytruda (pembrolizumab) • carboplatin • paclitaxel • pemetrexed • tobemstomig (RG6139)
    1year
    A Study of RO7247669 Alone or in Combination with Tiragolumab Versus Atezolizumab in Patients with Previously Untreated Locally Advanced or Metastatic Urothelial Bladder Cancer who are Ineligible for Platinum-Containing Chemotherapy (clinicaltrialsregister.eu)
    P2, N=240, Ongoing, F. Hoffmann-La Roche Ltd
    New P2 trial • Combination therapy • Metastases
    |
    PD-L1 (Programmed death ligand 1)
    |
    Tecentriq (atezolizumab) • tiragolumab (RG6058) • tobemstomig (RG6139)
    over1year
    A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Liver) (clinicaltrials.gov)
    P1/2, N=320, Recruiting, Hoffmann-La Roche | Trial completion date: Jul 2025 --> Dec 2025 | Trial primary completion date: Jul 2025 --> Dec 2025
    Trial completion date • Trial primary completion date • Metastases
    |
    PD-L1 (Programmed death ligand 1)
    |
    Avastin (bevacizumab) • Tecentriq (atezolizumab) • TPST-1120 • Actemra IV (tocilizumab) • tiragolumab (RG6058) • muzastotug (ADG126) • tobemstomig (RG6139)
    over1year
    A Study of RO7247669 Alone or in Combination With Tiragolumab vs Atezolizumab in Participants With Untreated Locally Advanced or Metastatic Urothelial Cancer (clinicaltrials.gov)
    P2, N=240, Recruiting, Hoffmann-La Roche | Not yet recruiting --> Recruiting
    Enrollment open • Combination therapy • Metastases
    |
    PD-L1 (Programmed death ligand 1)
    |
    Tecentriq (atezolizumab) • tiragolumab (RG6058) • tobemstomig (RG6139)
    over1year
    A Study of RO7247669 Alone or in Combination With Tiragolumab vs Atezolizumab in Participants With Untreated Locally Advanced or Metastatic Urothelial Cancer (clinicaltrials.gov)
    P2, N=240, Not yet recruiting, Hoffmann-La Roche
    New P2 trial • Combination therapy • Metastases
    |
    PD-L1 (Programmed death ligand 1)
    |
    Tecentriq (atezolizumab) • tiragolumab (RG6058) • tobemstomig (RG6139)
    over1year
    A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Liver) (clinicaltrials.gov)
    P1/2, N=320, Recruiting, Hoffmann-La Roche | Trial completion date: Dec 2024 --> Jul 2025 | Trial primary completion date: Dec 2024 --> Jul 2025
    Trial completion date • Trial primary completion date
    |
    PD-L1 (Programmed death ligand 1)
    |
    Avastin (bevacizumab) • Tecentriq (atezolizumab) • TPST-1120 • Actemra IV (tocilizumab) • tiragolumab (RG6058) • tobemstomig (RG6139)
    almost2years
    Clinical activity, safety, and PK/PD from the first in human study (NP41300) of RO7247669, a PD1-LAG3 bispecific antibody (ESMO 2022)
    Conclusions RO7274669 has a favorable safety profile and has shown encouraging anti-tumor activity in the dose escalation phase. Expansion cohorts in CPI experienced Melanoma and NSCLC as well as CPI naive ESCC are ongoing.
    Clinical • P1 data • PK/PD data
    |
    PD-1 (Programmed cell death 1) • LAG3 (Lymphocyte Activating 3) • PD-L2 (Programmed Cell Death 1 Ligand 2)
    |
    tobemstomig (RG6139)
    almost2years
    A Study of Multiple Doses of RO7247669 in Participants With Previously Untreated Unresectable or Metastatic Melanoma (clinicaltrials.gov)
    P2, N=80, Recruiting, Hoffmann-La Roche | Not yet recruiting --> Recruiting
    Enrollment open
    |
    PD-L1 (Programmed death ligand 1) • BRAF (B-raf proto-oncogene)
    |
    BRAF mutation • BRAF V600
    |
    tobemstomig (RG6139)
    almost2years
    A Study of Multiple Doses of RO7247669 in Participants With Previously Untreated Unresectable or Metastatic Melanoma (clinicaltrials.gov)
    P2, N=80, Not yet recruiting, Hoffmann-La Roche
    New P2 trial
    |
    PD-L1 (Programmed death ligand 1) • BRAF (B-raf proto-oncogene)
    |
    BRAF mutation • BRAF V600
    |
    tobemstomig (RG6139)
    2years
    A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Liver) (clinicaltrials.gov)
    P1/2, N=280, Recruiting, Hoffmann-La Roche | Trial completion date: Jul 2024 --> Dec 2024 | Trial primary completion date: Jul 2024 --> Dec 2024
    Trial completion date • Trial primary completion date
    |
    PD-L1 (Programmed death ligand 1)
    |
    Avastin (bevacizumab) • Tecentriq (atezolizumab) • TPST-1120 • Actemra IV (tocilizumab) • tiragolumab (RG6058) • SAR439459 • tobemstomig (RG6139)
    2years
    A Study of RO7121661 and RO7247669 Compared With Nivolumab in Participants With Advanced or Metastatic Squamous Cell Carcinoma of the Esophagus (clinicaltrials.gov)
    P2, N=210, Recruiting, Hoffmann-La Roche | Trial completion date: Oct 2024 --> May 2025 | Trial primary completion date: Oct 2024 --> May 2025
    Trial completion date • Trial primary completion date • IO biomarker
    |
    CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • LAG3 (Lymphocyte Activating 3) • HAVCR2 (Hepatitis A Virus Cellular Receptor 2) • CD4 (CD4 Molecule)
    |
    CD8 expression • LAG3 expression
    |
    Opdivo (nivolumab) • lomvastomig (RG7769) • tobemstomig (RG6139)
    over2years
    A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Liver) (clinicaltrials.gov)
    P1/2, N=280, Recruiting, Hoffmann-La Roche | Trial completion date: Oct 2024 --> Jul 2024
    Clinical • Trial completion date
    |
    PD-L1 (Programmed death ligand 1)
    |
    Avastin (bevacizumab) • Tecentriq (atezolizumab) • TPST-1120 • Actemra IV (tocilizumab) • tiragolumab (RG6058) • SAR439459 • tobemstomig (RG6139)
    almost3years
    A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Liver) (clinicaltrials.gov)
    P1/2, N=280, Recruiting, Hoffmann-La Roche | N=100 --> 280 | Trial completion date: Jul 2024 --> Oct 2024 | Trial primary completion date: Oct 2021 --> Jul 2024
    Clinical • Enrollment change • Trial completion date • Trial primary completion date
    |
    PD-L1 (Programmed death ligand 1)
    |
    Avastin (bevacizumab) • Tecentriq (atezolizumab) • TPST-1120 • Actemra IV (tocilizumab) • tiragolumab (RG6058) • SAR439459 • tobemstomig (RG6139)
    3years
    A Study of RO7121661 and RO7247669 Compared With Nivolumab in Participants With Advanced or Metastatic Squamous Cell Carcinoma of the Esophagus (clinicaltrials.gov)
    P2, N=255, Recruiting, Hoffmann-La Roche | Not yet recruiting --> Recruiting
    Clinical • Enrollment open • IO biomarker
    |
    CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • LAG3 (Lymphocyte Activating 3) • HAVCR2 (Hepatitis A Virus Cellular Receptor 2) • CD4 (CD4 Molecule)
    |
    CD8 expression • LAG3 expression
    |
    Opdivo (nivolumab) • lomvastomig (RG7769) • tobemstomig (RG6139)
    3years
    A Study of RO7121661 and RO7247669 Compared With Nivolumab in Participants With Advanced or Metastatic Squamous Cell Carcinoma of the Esophagus (clinicaltrials.gov)
    P2, N=255, Not yet recruiting, Hoffmann-La Roche
    Clinical • New P2 trial • IO biomarker
    |
    CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • LAG3 (Lymphocyte Activating 3) • HAVCR2 (Hepatitis A Virus Cellular Receptor 2) • CD4 (CD4 Molecule)
    |
    CD8 expression • LAG3 expression
    |
    Opdivo (nivolumab) • lomvastomig (RG7769) • tobemstomig (RG6139)
    over3years
    A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Liver) (clinicaltrials.gov)
    P1/2; N=100; Recruiting; Sponsor: Hoffmann-La Roche
    New P1/2 trial
    |
    PD-L1 (Programmed death ligand 1)
    |
    Avastin (bevacizumab) • Tecentriq (atezolizumab) • TPST-1120 • Actemra IV (tocilizumab) • tiragolumab (RG6058) • SAR439459 • tobemstomig (RG6139)